Isatuximab: a ‘next-generation monoclonal antibody’

Isatuximab: a ‘next-generation monoclonal antibody’

VJHemOnc

1 year
244 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about isatuximab, a revolutionary new antibody that has already been making waves in the multiple myeloma (MM) field. Dr Richardson explains why this antibody has been dubbed next-generation, despite being developed at the same time as many others, including daratumumab, before mentioning ICARIA-MM (NCT02990338), a trial aimed at determining the effects of isatuximab in combination with pomalidomide and dexamethasone.
Up Next Autoplay
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
Category: News
0 Views
Cancer-News 22 seconds
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
Category: Acute Lymphoblastic Leukemia
2 Views
alexvarney 19 hours
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Category: News
1 Views
Cancer-News 20 hours
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
1 Views
cancergrace 4 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
3 Views
Cancer-News 4 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
3 Views
Cancer-News 4 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 4 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 4 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
2 Views
Cancer-News 4 days